Rituximab in Antimelanoma Differentiation-Associated Protein-5 Dermatomyositis with Interstitial Lung Disease

المؤلفون المشاركون

Scirocco, Chiara
Gubbiotti, Andreina
Sebastiani, Alfredo
Sebastiani, Gian Domenico

المصدر

Case Reports in Rheumatology

العدد

المجلد 2020، العدد 2020 (31 ديسمبر/كانون الأول 2020)، ص ص. 1-5، 5ص.

الناشر

Hindawi Publishing Corporation

تاريخ النشر

2020-05-30

دولة النشر

مصر

عدد الصفحات

5

التخصصات الرئيسية

الأمراض

الملخص EN

In this paper, we report a challenging case of a middle-age woman who developed antimelanoma differentiation-associated protein-5 dermatomyositis (anti-MDA5 DM) with interstitial lung disease (ILD) and was successfully treated with rituximab (RTX), after failure of a first-line therapy.

نمط استشهاد جمعية علماء النفس الأمريكية (APA)

Scirocco, Chiara& Gubbiotti, Andreina& Sebastiani, Alfredo& Sebastiani, Gian Domenico. 2020. Rituximab in Antimelanoma Differentiation-Associated Protein-5 Dermatomyositis with Interstitial Lung Disease. Case Reports in Rheumatology،Vol. 2020, no. 2020, pp.1-5.
https://search.emarefa.net/detail/BIM-1151178

نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)

Scirocco, Chiara…[et al.]. Rituximab in Antimelanoma Differentiation-Associated Protein-5 Dermatomyositis with Interstitial Lung Disease. Case Reports in Rheumatology No. 2020 (2020), pp.1-5.
https://search.emarefa.net/detail/BIM-1151178

نمط استشهاد الجمعية الطبية الأمريكية (AMA)

Scirocco, Chiara& Gubbiotti, Andreina& Sebastiani, Alfredo& Sebastiani, Gian Domenico. Rituximab in Antimelanoma Differentiation-Associated Protein-5 Dermatomyositis with Interstitial Lung Disease. Case Reports in Rheumatology. 2020. Vol. 2020, no. 2020, pp.1-5.
https://search.emarefa.net/detail/BIM-1151178

نوع البيانات

مقالات

لغة النص

الإنجليزية

الملاحظات

Includes bibliographical references

رقم السجل

BIM-1151178